Assessing new therapies for RA: defining new expectations for treatment. New therapies in clinical practice: issues of cost and access.
D018501:Antirheumatic Agents / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics*; D002986:Clinical Trials as Topic; D016527:Drug Costs; D006297:Health Services Accessibility; D006801:Humans; D008329:Managed Care Programs; D008511:Medicine; D008991:Monitoring, Physiologic; D013038:Specialization; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014481:United States
D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha